Healthcare Professionals
Important Safety Information
Healthcare Professionals
Sign Up for Support

Frequently asked
questions
and
glossary of terms

Actor portrayal.

Frequently asked questions (FAQs)

Here are some questions that people often have when facing non–small cell lung cancer (NSCLC) and considering treatment with RYBREVANT FASPRO™ or RYBREVANT®. Ask your doctor if either of these treatments are right for you. If you have questions about a specific word or term, check the glossary below.

About RYBREVANT FASPRO™ and RYBREVANT®

RYBREVANT FASPRO™ and RYBREVANT® are both made out of targeted antibodies that work against EGFR mutations. Both are different than chemotherapy, immunotherapy, and TKIs (tyrosine kinase inhibitors).

RYBREVANT® is an infusion given into your vein through an intravenous (IV) line. You’ll be given infusions at your doctor’s office or an infusion center. Your doctor will decide how many doses you will receive, the time between doses, and the appropriate dose of each RYBREVANT® infusion based on your body weight.

RYBREVANT FASPRO™ is given as a ~5-minute injection under the skin (subcutaneous) in the stomach area (abdomen). This refers to how long your injection takes. You may receive more than 1 injection during your visit. Your care team will also give you other medications and check on how you're doing before you leave your visit.

You'll be given injections by your healthcare provider at your doctor's office. Depending on your dosing plan, you will receive your medicine every 2, 3, or 4 weeks (after the first 4 injections, which are given weekly).

Your doctor will decide the appropriate dose of RYBREVANT FASPRO™ based on your body weight and determine how often you will get injections.

About mutations and biomarkers

RYBREVANT FASPRO™ and RYBREVANT® are made of antibodies that target EGFR mutations. To help determine if RYBREVANT FASPRO™ or RYBREVANT® is right for you, your doctor may perform a biomarker test. These tests can check your tumor for different biomarkers, including EGFR, and can help guide your doctor to the appropriate treatment. Learn more about biomarkers here, and ask your doctor if an EGFR biomarker test is right for you.

A protein called an epidermal growth factor receptor (EGFR) is found on both normal cells and cancer cells. It drives cells to survive and grow. EGFR mutations may cause cancer cells to overgrow and spread to other parts of the body. Learn more about EGFR mutations here.

General questions

The 2 most common types of lung cancer are non–small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). The difference between these types is how the cancer cells look under a microscope and the different treatments approved for use for each. NSCLC is the most common type of lung cancer. About 85% of all lung cancer cases are NSCLC. Learn more about lung cancer here.

There are things you should know and do before you begin treatment with RYBREVANT FASPRO™ or RYBREVANT®. Learn about the steps you can take that will help you have the best possible treatment experience.

  • Learn how to prepare for RYBREVANT FASPRO™ + LAZCLUZE® (lazertinib) or RYBREVANT® + LAZCLUZE® as a first treatment for NSCLC with EGFR exon 19 deletions or exon 21 L858R mutations here
  • Learn how to prepare for RYBREVANT FASPRO™ + chemotherapy or RYBREVANT® + chemotherapy as a second treatment for NSCLC with EGFR exon 19 deletions or exon 21 L858R mutations here
  • Learn how to prepare for RYBREVANT FASPRO™ + chemotherapy or RYBREVANT® + chemotherapy as a first treatment for NSCLC with EGFR exon 20 insertion mutations here
  • Learn how to prepare for RYBREVANT FASPRO™ or RYBREVANT® as a second treatment for NSCLC with EGFR exon 20 insertion mutations here

If you have any medical questions, you should always ask your doctor.

Once you and your doctor have decided that a RYBREVANT FASPRO™–based or RYBREVANT®-based treatment is right for you, sign up for RYBREVANT withMe support

RYBREVANT withMe: Personalized 1-on-1 Support

You have access to free, dedicated support. Your Care Navigator is here to help guide you to support solutions throughout your treatment journey, so you feel informed and empowered.

Starting a new medicine can be overwhelming, and you may still have questions. We are here to help.

Free, 1-on-1 dedicated Care Navigator Support

Cost support options regardless of your insurance type

Additional resources and community connections

Sign up for personalized support throughout your treatment journey now by visiting RYBREVANTWithMe.com, or by calling 833-JNJ-wMe1 (833-565-9631), Monday through Friday, 8:00 AM–8:00 PM ET.

The support and resources provided by RYBREVANT withMe are not intended to provide medical advice, replace a treatment plan you receive from your doctor or nurse, or serve as a reason for you to start or stay on treatment.

Glossary of common terms and phrases

Below are definitions of common terms and phrases you may hear while living with non–small cell lung cancer and considering treatment with RYBREVANT FASPRO™or RYBREVANT®.

Antibodies are protective proteins that help detect harmful substances and diseases such as cancers. They are made naturally by your immune system and can also be man-made. Man-made antibodies used to treat cancer have a specific target on a cancer cell that they aim to find, attach to, and attack.

A biomarker is any molecule that can help show when your body is working normally or abnormally. This includes mutations in certain cells associated with advanced NSCLC.

A biomarker test identifies biomarkers by testing body tissue, blood, or other bodily fluids and can help your doctor determine which treatment is best for you.

Therapy that combines more than one method of treatment.

The amount of medicine given at one time.

The EGFR protein is involved in controlling cell division and survival. Sometimes, mutations (changes) in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer. This causes cancer cells to divide more rapidly.

There are 2 EGFR mutations that represent 80% to 90% of all EGFR mutations in NSCLC. These are called “exon 19 deletion” and “exon 21 L858R substitution.”

One kind of EGFR mutation is called an “exon 20 insertion” mutation. While rare, exon 20 insertion mutations are the third most frequent EGFR mutation in NSCLC, and can occur regardless of smoking history.

A method of putting fluids, including medicines, into the bloodstream through a vein.

The spread of cancer from the primary site (place where it started) to other places in the body. This is also called “advanced” cancer.

Any change in the DNA sequence of a cell. Mutations may be caused by mistakes during cell division, or they may be caused by exposure to DNA-damaging agents in the environment. Certain mutations may lead to cancer or other diseases. A mutation is sometimes called a “variant.”

A result of a medicine that is separate or in addition to the medicine's use for treatment.

  • Learn more about the possible side effects of RYBREVANT FASPRO™ or RYBREVANT® + LAZCLUZE® as a first treatment for NSCLC with EGFR exon 19 deletions or exon 21 L858R mutations here
  • Learn more about the possible side effects of RYBREVANT FASPRO™ or RYBREVANT® + chemotherapy as a second treatment for NSCLC with EGFR exon 19 deletions or exon 21 L858R mutations here
  • Learn more about the possible side effects of RYBREVANT FASPRO™ or RYBREVANT® + chemotherapy as a first treatment for NSCLC with EGFR exon 20 insertion mutations here
  • Learn more about the possible side effects of RYBREVANT FASPRO™ or RYBREVANT® as a second treatment for NSCLC with EGFR exon 20 insertion mutations here

Something that a person feels or experiences that may indicate that they have a disease or condition. Some examples of symptoms are pain, nausea, fatigue, and anxiety.

Elderly woman smiling happily outdoors
Elderly woman smiling happily outdoors

Savings & support

Once prescribed RYBREVANT FASPRO™ or RYBREVANT®, connect with a Care Navigator for your support needs.

The support and resources provided by RYBREVANT withMe are not intended to provide medical advice, replace a treatment plan you receive from your doctor or nurse, or serve as a reason for you to start or stay on treatment.